Rising profit at WuXi Biologics underscores drug sector rebound
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back…
Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market
Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs) Key points: dMed-Clinipace’s raises $50 million in the…
Recent Articles
RELATED ARTICLES
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK -
Fortune smiles again on WuXi AppTec with profit surge
2359.HK 603259.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK 603127.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK 600276.SHG
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
